Skip to main content

Table 1 Patients' characteristics

From: Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

  No of patients %
Number of patients enrolled 53  
Age (years)   
Median (range) 65 (18 – 78)  
Sex   
   Male 30 56.6
   Female 23 43.4
Performance status (WHO)   
   0 26 49
   1 20 37.7
   2 7 13.2
Tumor Origin   
   Colon 36 67.9
   Rectum 17 32.1
Prior Treatment   
   Surgery 39 73.6
   Adjuvant chemotherapy 13 24.5
   Adjuvant radiotherapy 6 11.3
Abnormal ALP # level at baseline 21 39.6
Abnormal WBC^ level at baseline 10 18.9
Abnormal PLT* level at baseline 6 11.3
Kohne prognostic index   
   Low risk 11 20.7
   Intermediate risk 30 56.6
   High risk 12 22.6
Sites of disease   
   Local Abdominal Mass 11 20.7
   Liver 34 64.2
   Lung 18 34
   Lymph Nodes 17 32
Number of metastatic sites   
   1 14 26.4
   2 30 56.6
   ≥ 3 median 9 17
Median (range) 2 (1–5)
  1. #ALP: Alkaline Phosphatase, ^WBC: White cells Blood Count, *PLT: Platelets